Wednesday, October 21, 2026 | 12am EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central)

As artificial intelligence becomes increasingly embedded in pharmacovigilance operations, QPPVs and Safety Leaders face a new challenge: how to embrace AI-driven innovation while maintaining regulatory compliance, effective oversight and clear human accountability.

Join PrimeVigilance experts Jana D’Alascio, Senior Director, QPPV, and Nikodem Latocha, Associate Director Quality – Computerized Systems Quality, for a practical discussion on the evolving regulatory landscape for AI-enabled pharmacovigilance.

The session will explore current AI adoption across PV workflows, emerging expectations from global health authorities and the implications of the EU AI Act and other evolving requirements for GxP environments. Our experts will also examine what these developments mean for the role of the QPPV, including how organizations can establish appropriate governance boundaries, define and document AI decision-making parameters, and remain inspection-ready as technology continues to evolve.